The U.S. Food and Drug Administration (FDA) approved a supplemental application for Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) on November 22, 2024. This approval specifically addresses the efficacy of the combination product, indicating an update or expansion related to its demonstrated effectiveness.
Background
Phesgo is a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf. Pertuzumab and trastuzumab are monoclonal antibodies. The inclusion of hyaluronidase-zzxf facilitates subcutaneous administration of the antibodies. This supplemental approval pertains to the efficacy of the product, suggesting an update or confirmation of its therapeutic benefits in its indicated use.
What this means
The FDA's approval of a supplemental application for Phesgo regarding its efficacy signifies an important development for the product. While specific details of the updated efficacy information are not provided in the approval summary, such approvals often relate to new or expanded indications, different patient populations, or refined dosing regimens that demonstrate improved or confirmed effectiveness. This type of approval reinforces the therapeutic value of Phesgo and may broaden its clinical utility for healthcare providers and patients.
Source
Information regarding the supplemental approval for Phesgo was obtained from the U.S. Food and Drug Administration (FDA). The approval, classified as an efficacy supplement (BLA 761170 S-7), was granted on November 22, 2024, and is publicly available on accessdata.fda.gov.